Target
EGFR T790M
8 products, 10 indications
Indications
EGFR-mutated advanced NSCLC with atypical mutations (3 products)
EGFR-mutant T790M-positive non-small cell lung cancer (2 products)
EGFRm+ NSCLC with CNS metastasis (2 products)
advanced non-squamous NSCLC (2 products)
advanced EGFR-mutated NSCLC (2 products)
NSCLC with EGFR mutations and ALK rearrangements with brain metastases (1 products)
NSCLC with EGFR exon 19 deletion or L858R (1 products)
NSCLC (1 products)
NSCLC with other uncommon non-ex20ins EGFR mutations (1 products)
EGFR ex20ins-mutant NSCLC (1 products)
Loading...
3 drugs
3 abstracts
Abstract
Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI, in patients with 3rd generation EGFR-TKI resistance in EGFR mutated advanced/metastatic non-small cell lung cancer (NSCLC).Org: J INTS BIO Inc., Ramathibodi Hospital,
Abstract
Real-world outcomes of osimertinib in Peruvian patients with advanced NSCLC with EGFR T790M-positive: A multi-institutional experience.Org: Hospital Centro Médico Naval, Hospital Nacional PNP, Hospital Central FAP, Clinica Good Hope,
Abstract
A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-cell lung cancer (LC-SCRUM-TRY).Org: National Cancer Center Hospital East, Kashiwa, Japan, Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, Osaka International Cancer Institute, Osaka, Japan, Kanagawa Cancer Center, Itami City Hospital,
Drug
rezivertinibDrug
lorigerlimabDrug
lazertinib